Hereditary angiodema: a current state-of-the-art review, IV: short- and long-term treatment of hereditary angioedema: out with the old and in with the new?
OBJECTIVE
To provide a context to understand the opportunity for novel therapeutic modalities to transform the treatment of hereditary angioedema (HAE).


METHODS
MEDLINE and PubMed were searched to identify studies involving current treatment of HAE in the United States.


METHODS
Studies were selected based on their relevance to the treatment of HAE.


RESULTS
The current HAE treatment strategy is far from satisfactory, and its limitations create an unmet clinical need. Current prophylactic treatment exposes patients with HAE to significant risk of adverse effects, and the efficacy of prophylactic treatment, although generally good, is far from perfect.


CONCLUSIONS
No specific treatment is currently available in the United States for acute HAE attacks that will reliably work, resulting in a significant unmet clinical need. The emergence of several promising drugs for the treatment of HAE attacks is, thus, an extraordinarily important development in the management of these patients.
Zuraw
Bruce L
BL
Veterans Affairs Medical Center, San Diego, California, USA. bzuraw@ucsd.edu
D015119:Aminocaproic Acid / Q000627:therapeutic use; D045930:Anabolic Agents / Q000627:therapeutic use; D000728:Androgens / Q000627:therapeutic use; D054179:Angioedemas, Hereditary / Q000175:diagnosis / Q000628:therapy*; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D001803:Blood Transfusion; D002986:Clinical Trials as Topic; D050718:Complement C1 Inhibitor Protein / Q000627:therapeutic use; D003613:Danazol / Q000627:therapeutic use; D004965:Estrogen Antagonists / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D006801:Humans; D007610:Kallikreins / Q000037:antagonists & inhibitors; D010455:Peptides / Q000627:therapeutic use
D045930:Anabolic Agents; D000728:Androgens; D000933:Antifibrinolytic Agents; D050718:Complement C1 Inhibitor Protein; D004965:Estrogen Antagonists; D010455:Peptides; D007610:Kallikreins; D003613:Danazol; D015119:Aminocaproic Acid